Wegovy Gets NICE Recommendation and Novo Nordisk Plans UK Launch
March 8, 2023
The UK’s National Institute for Health and Care Excellence (NICE) gave Novo Nordisk’s weight loss drug Wegovy its recommendation for coverage today, March 8th. In response, Novo Nordisk is making plans to bring the wildly popular drug to the UK market. However, the drug will be more tightly controlled than in the US or EU markets, where the drug has taken off with celebrities and influencers.
According to Angus Liu, “For people with a BMI between 30 to 34.9, only those at the highest risk should be considered for treatment under a special weight management service, NICE said. These patients have complex disease states or have failed on conventional treatment. For those with a BMI of at least 35, Wegovy will be available through an NHS weight specialist, NICE said. NICE’s BMI requirement is stricter than Wegovy’s European label. The U.K. Medicines and Health Products Regulations Agency approved Wegovy in September 2021 to treat people with a BMI as low as 27, accompanied by at least one weight-related comorbidity.”
To read more, click here.
(Source: Fierce Pharma, March 8th, 2023)